specialty-drugs
(2)
Mandolin
Mandolin is a San Francisco healthcare AI company building agents that handle the paperwork blocking patients from specialty drugs. Its software automates intake, benefits verification, prior authorization, and claims work for infusion providers, specialty pharmacies, and health systems - the back office that decides how quickly a cancer or Alzheimer's patient actually gets treated.
Will Yin
Will Yin is the co-founder and CEO of Mandolin, a San Francisco AI automation company building autonomous agents for specialty drug access. A Greenwich High School valedictorian and Stanford dropout, Yin previously co-founded Jupiter (YC-backed, $9M raised) before pivoting to healthcare. At Mandolin, he and co-founder Rohit Rustagi have raised $97M to automate the back-office workflows — prior auth, benefits verification, billing — that delay cancer and Alzheimer's patients from getting life-saving specialty therapies. Within months of launch, Mandolin deployed across 700+ clinics serving 250,000+ new patients annually.